Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2008
11/18/2008US7452543 Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics
11/18/2008US7452535 Methods of treatment using CTLA-4 antibodies
11/18/2008CA2519252C Biaryl substituted triazoles as sodium channel blockers
11/18/2008CA2440222C Triazolopyridines as anti-inflammatory agents
11/18/2008CA2422379C Pyrazole compounds useful as protein kinase inhibitors
11/18/2008CA2397537C External plaster containing 4-biphenylyl acetic acid
11/18/2008CA2381219C Monomeric protein of the tgf-beta family
11/18/2008CA2358487C Use of phanquinone for the treatment or prevention of memory impairment
11/18/2008CA2344057C Treatment of persistent pain
11/18/2008CA2339190C Compressed compositions comprising clarified xanthan gum
11/18/2008CA2326809C Solid, quick dissolving cetirizine formulations
11/18/2008CA2320822C Substituted isoindolones and their use as cyclic gmp modulators in medicaments
11/18/2008CA2314326C Transdermal therapeutic device and method with capsaicin and capsaicin analogs
11/18/2008CA2301899C Agent with an antidepressant activity
11/18/2008CA2301725C Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
11/18/2008CA2296492C Use of compositions containing the combination of acetaminophen, aspirin and caffeine to alleviate the pain and symptoms of migraine
11/18/2008CA2277791C Oxcarbazepine film-coated tablets
11/18/2008CA2264941C Use of a combination of an atypical antipsychotic and a serotonin reuptake inhibitor for treatment of psychosis
11/18/2008CA2245125C Use of one extract of at least one rosaceae plant
11/18/2008CA2143752C Method of preventing nmda receptor-mediated neuronal damage
11/18/2008CA2107884C Use of vasoactive intestinal peptide (vip) to induce temporary paralysis of the gastrointestinal tract
11/18/2008CA1341585C Recombinant retroviruses
11/13/2008WO2008137720A2 Peptide analogs that are potent and selective for human neurotensin receptor subtype 2
11/13/2008WO2008137461A1 Naphthyl(ethyl) acetamides
11/13/2008WO2008137139A1 Gamma secretase modulators
11/13/2008WO2008137137A1 Creatine ascorbyl derivatives and methods of use thereof
11/13/2008WO2008137134A2 Amorphous eletriptan hydrobromide and process for preparing it and other forms of eletriptan hydrobromide
11/13/2008WO2008137012A1 Use of a glial attenuator to prevent amplified pain responses caused by glial priming
11/13/2008WO2008136838A1 Novel amide derivatives of cddo and methods of use thereof
11/13/2008WO2008136756A1 Pyrrolopyrimidin-7-one derivatives and their use as pharmaceuticals
11/13/2008WO2008136695A1 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine-beta-hydroxylase
11/13/2008WO2008136511A1 Therapeutic agent for diabetic neuropathy
11/13/2008WO2008136444A1 Fused heterocyclic derivative
11/13/2008WO2008136382A1 Bicyclic compound and pharmaceutical use thereof
11/13/2008WO2008136377A1 Bicyclic heterocyclic compound
11/13/2008WO2008136374A1 Pharmaceutical composition for inhibiting peripheral neuropathy caused by the administration of anticancer agent
11/13/2008WO2008136017A1 Aminoalkoxy aryl sulfonamide compounds and their use as 5-ht6 ligands
11/13/2008WO2008135984A1 Composition comprising s-allylmercapto-n-acetylcysteine (assnac) for up-regulation of cellular glutathione level
11/13/2008WO2008135830A1 N- [6-amino-5- (phenyl) pyrazin-2-yl] -isoxazole-4-carboxamide derivatives and related compounds as nav1.8 channel modulators for the treatment of pain
11/13/2008WO2008135826A2 2 -pyridine carboxamide derivatives as sodium channel modulators
11/13/2008WO2008135743A1 Substituted phosphonates and their use in decreasing amyloid aggregates
11/13/2008WO2008135661A2 Use of citrulline for the treatment of conditions linked to an increase in protein carbonylation
11/13/2008WO2008135639A2 Novel useful inhibitors
11/13/2008WO2008135527A2 Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
11/13/2008WO2008135522A1 Use of s1p receptor modulator
11/13/2008WO2008135488A1 Aspartyl protease inhibitors
11/13/2008WO2008135041A1 Adamantyloxyamine derivatives and related compounds for use as nmda and/or dpp-4 modulators for the therapy of cns diseases and diabetes
11/13/2008WO2008134919A1 Ejaculum of animals as medicinal material and uses thereof in medicaments for treatment of diseases such as tumors, depression, etc.
11/13/2008WO2008115098A3 Substituted 2,3,4,5-tetrahydro-1h-pyrido[4,3-b]indoles, methods for the production and the use thereof
11/13/2008WO2008113360A3 4- [2- (4-methylphenylsulfanyd-phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of adhd, melancholia, treatment resistent depression or residual symptoms in depression
11/13/2008WO2008113359A3 1- [2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of pain or residual symptoms in depression relating to sleep and cognition
11/13/2008WO2008112641A3 Methods and compositions for treating thalamocortical dysrhythmia
11/13/2008WO2008112319A3 Methods of treating parkinson's disease using halogenated volatile compounds
11/13/2008WO2008107862A3 Use of ngf for the preparation of medicaments for the cure of reactive gliosis
11/13/2008WO2008103461A3 Solid forms comprising (-) o-desmethylvenlafaxine and uses thereof
11/13/2008WO2008065500A3 Heteroaryl amides as type i glycine transport inhibitors
11/13/2008WO2008037707A3 Valerian extract preparation
11/13/2008WO2008011596A3 Hydrophilic abuse deterrent delivery system
11/13/2008WO2008011595A3 Hydrophobic abuse deterrent delivery system
11/13/2008WO2007145563A8 Benzimidazole derivatives which are to be used as antagonist for the cb1-receptor
11/13/2008WO2007113885A8 Solid oral compositions based on s-adenosyl methionine and/or nadh and process for obtaining them
11/13/2008US20080280993 Treatment of CNS Disorders With trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine
11/13/2008US20080280990 administering -[(1-RS, 2-SR)-2-[(dimethylamino)methyl]-1-hydroxycyclohexyl]-benzamide or isomers for the treatment of pain and as agents for treating or modulating central nervous system disorders
11/13/2008US20080280983 Methods of treating rett syndrome
11/13/2008US20080280969 (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide; neuropathic or inflammatory pain; modulation of use-dependent voltage-gated sodium channels
11/13/2008US20080280965 Novel tetrahydrocarbazole derivatives having improved biological action and improved solubility as ligands of G-protein coupled receptors (GPCPs)
11/13/2008US20080280956 Heteroarylsulfonyl Stilbenes as 5-Ht2a Antagonists
11/13/2008US20080280954 Method of Improving Wakefulness
11/13/2008US20080280949 Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators
11/13/2008US20080280947 Anti-insomnia compositions and methods
11/13/2008US20080280942 Tetrahydro-Beta-Carbolin-Sulfonamide Derivatives as 5-Ht6 Ligands
11/13/2008US20080280941 8-Phenoxy-Gamma Carboline Derivatives
11/13/2008US20080280936 Morphinan Compounds
11/13/2008US20080280933 Benzimidazolyl compounds
11/13/2008US20080280928 Pyrrolopyrimidine and Pyrrolopyridine Derivatives Substituted with a Cyclic Amino Group As Crf Antagonists
11/13/2008US20080280919 Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
11/13/2008US20080280917 Nitrogen-Containing heterocyclyl ketones and methods of use
11/13/2008US20080280913 dipeptidyl-peptidase IV (DPP-IV) inhibitors such as 5,5,6,6,8,8-d6-3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine; increasing hormone glucagon-like peptide levels; pharmacokinetics; side effect reduction
11/13/2008US20080280912 Diagnosis test; mixing blood or other fluid sample with test compound; analyzing, calibration; central nervous system disorders; analgesics; antiinflamamtory agents; drug abuse; anxiolytic agents; cognition activators;Alzheimer's disease; Parkinson's disease; Huntington's disease; hyperactivity
11/13/2008US20080280909 New phenylalanine derivatives
11/13/2008US20080280908 N-(2-(7-(methoxy-d3)-naphthalen-1-yl)ethyl)acetamide-d3, a deuterated derivative of Agomelatine; side effect reduction; decreased metabolic liability; pharmakinetics; bioavailability;antidepressants; anxiolytic agents; bipolar disorders; dual melatoninergic agonist and serotoninergic antagonist
11/13/2008US20080280898 5-Bromo-1'-[(3-methyl-1H-inden-2-yl)carbonyl]spiro[indole-3,4'-piperidin]-2(1H); vasopressin receptor antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder
11/13/2008US20080280894 DIHYDRO[1,4]OXAZINO[2,3,4-hi]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
11/13/2008US20080280893 SUBSTITUTED-DIHYDRO[1,4]OXAZINO[2,3,4-hi]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
11/13/2008US20080280887 Selected Cgrp-Antagonists, Processes for Preparing Them and Their Use as Pharmaceutical Compositions
11/13/2008US20080280886 Substituted ureas
11/13/2008US20080280885 Methods for Treating Anxiety Related Disorders
11/13/2008US20080280882 Novel Substituted Diazabicyclo Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors
11/13/2008US20080280876 Sphingosine-1-phosphate (S1P) receptor agonists or antagonists; immunosuppressants; e.g. 3-(3-chloro-4-isopropoxyphenyl)-5-(p-(3-carboxyazetidin-1-ylmethyl)phenyl)-1,2,4-oxadiazole; two specific compounds are excluded
11/13/2008US20080280870 Beta-Lactamyl Phenylalanine, Cysteine, and Serine Vasopressin Antagonists
11/13/2008US20080280863 Concurrent administering by mouth a corticosteroid and tricyclic antidepressant compound; immunoinflamamtory disorders; antiarthritic agents; skin disorders; inflammatory bowel disorders; Crohn's disorders; autoimmune disease; asthma; multiple sclerosis; diabetes; lupus
11/13/2008US20080280857 ligands for Calcitonin gene related peptide; azepinone ligands; migranes; N-[5-(2,3-Difluorophenyl)-1-(2-methoxyethyl)-2-oxopiperidin-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide
11/13/2008US20080280856 Fibroblast Activation Protein Inhibitor Compounds and Methods
11/13/2008US20080280835 Peptides illustrated by lacosamide ((R)-2-acetamide-N-benzyl-3-methoxypropionamide)
11/13/2008US20080280824 Compositions and methods for treatment of cancer or neurodegenerative disease with peptide based microtubule stabilizers or inhibitors
11/13/2008US20080280308 G protein coupled receptor signaling modulation
11/13/2008US20080280301 Using transmembrane serine protease expression as evaluative tool in detection of nervous system stem cells; regenerative medicine; tissue engineering; treating neurodegenerative
11/13/2008US20080279969 Composition Comprising Bamboo Extract for Androgen Agonist
11/13/2008US20080279952 Controlling particle size; overcoating particles; pain therapy eith postoperative or tumor pain; central nervous system disorders; antiepileptic agents; Parkinson's disease; longQT syndrome; potassium channel moderators; muscular disorders; prion disease; Alzheimer's disease; tinnitus ; overactive bladde
11/13/2008US20080279932 Vildagliptin salt; in mixture with therapeutic agents such as antidiabetic agents; antilipemic agents; obesity; appetite control; hypotensive agents; cholesterol absorption moderators; anticoagulants; estrogen receptor moderators; transferring across blood-brain barrier
1 ... 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 ... 1833